<DOC>
	<DOCNO>NCT01140126</DOCNO>
	<brief_summary>The purpose Phase I study determine whether antibody ( UB-421 ) , target HIV-1 receptor CD4 molecule ( domain 1 ) T-lymphocytes monocyte , safe well tolerate administer asymptomatic HIV-1 infect adult intravenous infusion ass pharmacokinetic parameter antibody blood cell . The neutralizing activity UB-421 block HIV-1 bind receptor CD4-positive cell ; thus , UB-421 function immunotherapeutic intervention prevent HIV-1 infection .</brief_summary>
	<brief_title>Study Evaluate Safety Pharmacokinetics UB-421 Antibody HIV-1 Infected Adults</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Asymptomatic , treatmentnaive , HIV1 seropositive CD4+ T cell count &gt; 350 cells/cubic millimeter HIV1 viral load &gt; 5,000 copies/mL Other inclusion criterion apply Active infection require immediate therapy ( except HIV1 ) Prior participation HIV vaccine trial Previous exposure monoclonal antibody Use immunomodulating drug systemic chemotherapy Other exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>HIV-1 , CD4 , antibody , immunotherapy</keyword>
</DOC>